Skip to main content

Table 2 Univariate analysis for recurrence-free survival and overall survival

From: Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer

 

OS

RFS

P

HR

95% CI

P

HR

95% CI

Age

0.099

1.524

0.924–2.512

0.622

1.123

0.708–1.781

Comorbidities

 CCI < 3

0.018

1.842

1.111–3.054

0.131

1.429

0.899–2.273

 CCI ≥3

Grade

 Well/Moderate

0.256

1.408

0.780–2.540

0.094

1.606

0.922–2.796

 Poor

Lymphovascular invasion

0.844

1.058

0.603–1.856

0.121

1.528

0.894–2.613

Perineural invasion

0.152

1.799

0.806–4.016

0.033

2.262

1.070–4.781

pT stage

 1–2

0.786

1.072

0.649–1.769

0.963

1.011

0.636–1.607

 3–4

Lymph node involvement

0.178

1.423

0.852–2.375

0.063

1.573

0.976–2.535

Pathologic stage

 I-II

0.588

1.150

0.694–1.907

0.495

1.175

0.739–1.868

 III-IV

Resection margin

 Negative

0.728

1.092

0.665–1.793

0.715

0.918

0.579–1.454

 Positive

Treatment

 Adjuvant CCRT

0.224

1.378

0.822–2.309

0.016

1.802

1.118–2.904

 Adjuvant chemotherapy

  1. OS Overall survival, RFS Recurrence-free survival, HR Hazard ratio, CCI Charlson comorbidity index, CCRT Concurrent chemoradiation therapy